ENRGISE pilot study will inform larger trial of IL-6 in seniors

ENRGISE pilot study will inform larger trial of IL-6 in seniors
(HealthDay)—Data obtained from a pilot study, published online July 22 in the Journal of the American Geriatrics Society, will be used to plan a full-scale trial targeting interleukin (IL)-6 levels among older adults with low-to-moderate physical function.

Todd M. Manini, Ph.D., from the University of Florida in Gainesville, and colleagues conducted a multicenter randomized trial of two interventions to reduce IL-6 levels at five university-based research centers. The target enrollment was 300 men and women aged 70 years and older with an average plasma IL-6 level between 2.5 and 30 pg/mL and low-to-moderate physical function. The authors randomized participants to losartan, omega-3 fish oil (ω-3), combined losartan and ω-3, or placebo. In order to reach a dose that was safe and effective for IL-6 reduction, a titration schedule was implemented.

The researchers anticipate that results from the ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study will provide data on recruitment yields, feasibility, and medication tolerance and adherence. In addition, the trial will provide preliminary data to justify a larger sample size that can be used for a more definitive randomized trial.

"The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of with low-grade chronic inflammation and mobility limitations," the authors write.


Explore further

Structured physical activity results in small reduction in sedentary time among older adults

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: ENRGISE pilot study will inform larger trial of IL-6 in seniors (2017, July 27) retrieved 24 May 2019 from https://medicalxpress.com/news/2017-07-enrgise-larger-trial-il-seniors.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more